The emblem for the Meals and Drug Administration is seen forward of a information convention on the Well being and Human Providers Headquarters in Washington, April 22, 2025.
Nathan Posner | Anadolu | Getty Photos
A key U.S. Meals and Drug Administration official who oversees vaccines and biotech therapies will step down from the company following a number of choices that raised considerations inside the trade.
Vinay Prasad, director of the Middle for Biologics Analysis and Analysis, will depart the FDA on the finish of April, an company spokesperson confirmed on Friday. It’s his second departure from the place: He briefly left the submit in July following backlash over his regulatory choices, and returned solely two weeks later in August.
In a submit on X, FDA Commissioner Marty Makary mentioned the FDA will appoint a successor earlier than Prasad returns subsequent month to the College of California, San Francisco, the place he taught earlier than taking the FDA place final yr. Makary mentioned Prasad “bought an incredible quantity achieved” throughout his tenure on the company.
Prasad’s determination to step down comes after mounting criticism of the FDA inside the biotech and pharmaceutical industries and amongst former well being officers. Prior to now yr, the company has denied or discouraged the approval functions of at the very least eight medication, in line with RTW Investments, after taking problem with knowledge the businesses used to assist their functions. The FDA initially refused to overview Moderna’s flu shot, however later reversed course.
All of these firms accused the FDA of reversing earlier steerage on the proof they may use to assist their functions, sparking trade criticism that an unreliable regulatory course of might stifle the event of medicine for hard-to-treat illnesses.
A former FDA official who spoke to CNBC on the situation of anonymity to talk freely on the difficulty referred to as the reversals the worst sort of regulatory uncertainty as a result of firms say they’re being advised one factor after which expertise one other.
In a press release earlier Friday, an FDA spokesperson mentioned there was “no regulatory uncertainty,” including the company “makes choices primarily based on the proof, however doesn’t make assurances about outcomes.” The spokesperson mentioned the FDA is “conducting rigorous, unbiased evaluations and never rubber-stamping approvals.”
The latest controversy arose after the FDA discouraged UniQure from making use of for expedited approval of its experimental remedy for Huntington’s illness.
The company, which underwent employees cuts and an overhaul beneath Well being and Human Providers Secretary Robert F. Kennedy Jr., has confronted broader backlash for its drug and vaccine approval course of. Critics have apprehensive that the company might stifle the event of recent therapies and threat the security of sufferers.
Criticism of Prasad had been rising and reached a fever pitch when the FDA’s Makary, in an interview with CNBC’s Becky Fast final week, appeared to criticize UniQure’s gene remedy for Huntington’s illness. Makary did not title UniQure however described its remedy.
Requires a shakeup grew even louder at a CNBC Cures occasion this week.
The Wall Avenue Journal first reported Prasad’s departure.
